KRAS and pancreatic adenocarcinoma: As the KRAS oncogene is mutated in > 95% of pancreatic adenocarcinomas (Jones et al, 2008), inhibition of signaling pathway downstream of KRAS is considered to be an attractive therapeutic approach.